Form 4: PTC Therapeutics Executive VP Mark Boulding Reports Stock Option Exercise and Sale

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on May 15 and 16, 2025, according to a Form 4 filing with the SEC.

Summary

• Mark Boulding, an Executive VP and CLO at PTC Therapeutics, executed transactions involving the company's stock.
• On May 15, 2025, Boulding exercised stock options to acquire 1,929 shares at a price of $25.69 per share and then sold the same amount of shares at a weighted average price of $46.18 per share.
• On May 16, 2025, Boulding exercised stock options to acquire 883 shares at a price of $25.69 per share and then sold the same amount of shares at a weighted average price of $46.02 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2024.
• Following these transactions, Boulding still directly owns 103,901 shares of common stock and 27,712 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can be seen as a positive sign of transparency and planned financial management.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The vesting schedule of the options (25% after one year, then quarterly) is a fairly standard practice.
• The use of a 10b5-1 plan is a common and accepted method for executives to manage their stock sales.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the change in the number of outstanding shares, but the effect is likely minimal given the relatively small volume of shares traded.

Key Dates

Keywords

PTC Therapeutics, Mark Boulding, stock options, Form 4, insider trading, Rule 10b5-1, executive compensation, stock sale